concor amlo 10 mg/10 mg tabletten
merck healthcare germany gmbh (8128716) - amlodipinbesilat; bisoprololfumarat (ph.eur.) - tablette - teil 1 - tablette; amlodipinbesilat (24866) 13,9 milligramm; bisoprololfumarat (ph.eur.) (23549) 10 milligramm
concor amlo 10 mg/5 mg tabletten
merck healthcare germany gmbh (8128716) - amlodipinbesilat; bisoprololfumarat (ph.eur.) - tablette - teil 1 - tablette; amlodipinbesilat (24866) 6,95 milligramm; bisoprololfumarat (ph.eur.) (23549) 10 milligramm
concor amlo 5 mg/10 mg tabletten
merck healthcare germany gmbh (8128716) - amlodipinbesilat; bisoprololfumarat (ph.eur.) - tablette - teil 1 - tablette; amlodipinbesilat (24866) 13,9 milligramm; bisoprololfumarat (ph.eur.) (23549) 5 milligramm
concor amlo 5 mg/5 mg tabletten
merck healthcare germany gmbh (8128716) - amlodipinbesilat; bisoprololfumarat (ph.eur.) - tablette - teil 1 - tablette; amlodipinbesilat (24866) 6,95 milligramm; bisoprololfumarat (ph.eur.) (23549) 5 milligramm
blincyto
amgen europe b.v. - blinatumomab - vorläuferzelle lymphoblastische leukämie-lymphom - antineoplastische mittel - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
concor plus 5 mg/12,5 mg - filmtabletten
merck gesellschaft mbh - bisoprolol hemifumarat; hydrochlorothiazid - bisoprolol und thiazide
concor 10 plus
merck healthcare germany gmbh (8128716) - bisoprololfumarat (ph.eur.); hydrochlorothiazid - filmtablette - teil 1 - filmtablette; bisoprololfumarat (ph.eur.) (23549) 10 milligramm; hydrochlorothiazid (00512) 25 milligramm
concor 5 plus
merck healthcare germany gmbh (8128716) - bisoprololfumarat (ph.eur.); hydrochlorothiazid - filmtablette - teil 1 - filmtablette; bisoprololfumarat (ph.eur.) (23549) 5 milligramm; hydrochlorothiazid (00512) 12,5 milligramm
concor 5 plus filmtabletten
merck (schweiz) ag - bisoprololi fumaras, hydrochlorothiazidum - filmtabletten - filmtablette: bisoprololi fumaras 5.0 mg, hydrochlorothiazidum 12.5 mg, silica colloidalis anhydrica, magnesium stearas, cellulosum microcristallinum, maydis für amylum, calcium hydrogenophosphas, Überzug: dimeticonum, macrogolum 400, hypromellosum, e 171, e 172 (rot) e 172 (schwarz), für compresso dunst. - hypertonie - synthetika
concor 10 plus filmtabletten
merck (schweiz) ag - bisoprololi fumaras, hydrochlorothiazidum - filmtabletten - bisoprololi fumaras 10 mg, hydrochlorothiazidum 25 mg, silica colloidalis anhydrica, magnesium stearas, cellulosum microcristallinum, maydis für amylum, calcium hydrogenophosphas, Überzug: dimeticonum, macrogolum 400, hypromellosum, e 171, e 172 (rot) e 172 (schwarz), für compresso dunst. - hypertonie - synthetika